Phaseline

Targets › 3C

3C: drug programs, companies and trials

1 program from 1 company in 9 trials: 7 Phase 2, 1 Phase 3, 1 Phase 4; Infectious disease; next expected readout Sep 2027.

Open in Phaseline: the race on 3C, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerRemdesivir
RNA-directed RNA polymerase L inhibitor; Replicase polyprotein 1ab inhibitor
3C, RDRPPhase 3COVID-19 Infection; SARS CoV-2 Post-Acute Sequelae; COVID-19; COVID - 19 …Sep 2027

Conditions

COVID-19 (3) COVID-19 Infection (1) SARS CoV-2 Post-Acute Sequelae (1) COVID - 19 (1) Respiratory Syncytial Virus (RSV) (1) Hematopoietic and Lymphatic System Neoplasm (1) Dengue (1)

Modalities

small molecule (1)

Companies

Pfizer (1)

Related targets

RDRP (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.